Intuitive Surgical, Inc.

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company ended Q3 2024 with $8.3 billion in cash and investments, which increased from $7.7 billion in the prior quarter. - The firm expects declining average interest yields on cash and investments going into 2025 due to the interest rate environment. - Capital expenditures are projected between $1 billion and $1.2 billion for facility construction activities. - There is no discussion of issuing new debt or equity; instead, cash generation from operations appears sufficient to cover expenditures. - The focus is on managing operating margins, procedure growth, and product launches rather than raising additional capital at this time.

- Capital expenditures for 2024 are estimated in the range of $1 billion to $1.2 billion, primarily for planned facility construction activities. (Page 3) - Capital expenditures and investments include ongoing expansions such as the high-volume INA manufacturing facility in Mexicali to support product growth. (Page 3) - The trading cycle for da Vinci systems will be progressive over multiple years, with refurbishing and repurposing of traded-in systems planned, allowing for site-of-care segmentation internationally and in the U.S. (Page 4) - The company is prioritizing dual console production for da Vinci 5 as supply capabilities ramp, with plans to increase production quarter over quarter. (Page 4) - Overall, the midterm strategy balances investment in R&D and capital to support growth opportunities and efficient scaling. (Page 5)

- **Procedure Growth:** Full-year 2024 procedure growth expected between 16% and 17%, up from prior forecast of 15.5%-16%. - **U.S. Market:** Relatively stable capital environment; approaching later stages of existing procedure curves with opportunities to deepen penetration and serve new patient categories via new indications (Ion, SP, multiport niche markets). - **Europe:** Capital pressure due to government budget constraints; uncertain near-term impact, monitoring upcoming government events. - **China:** Broad healthcare market stress with value/pricing pressure and domestic competition; pressure expected to persist for multiple quarters before stabilizing. - **Da Vinci 5 System:** Progressive ramp-up with 110 systems placed in Q3 and positive early utilization feedback; broader adoption and upgrades expected into mid-2025 broad launch. - **Ion System:** Strong U.S. penetration with early international expansion; double-digit prevalence in lung biopsies in U.S. and early steps in Europe and China. - **Digital Tools (Hub):** Early-stage uptake with ~2,000 ORs; ongoing feature enhancements to support procedure growth.

- Full-year 2024 procedure growth is raised to 16%-17%, with stable headwinds in Asia expected to not worsen. - Pro forma gross profit margin forecast for 2024 remains between 68.5%-69%. - Operating expense growth for 2024 expected to be 10%-12%, down from a prior 10%-13% range. - No management objective to push operating margins above 40%, balancing growth investments and profitability; recent operating margins were ~37%. - Gross margins expected to be slightly lower in 2025 due to incremental depreciation expenses from new product facilities. - Pro forma EPS for Q3 2024 increased 25% year-to-date compared to prior year, with Q3 2024 GAAP EPS at $1.56 vs $1.16 prior year. - Capital expenditures expected between $1 billion and $1.2 billion primarily for facility construction. - Interest income expected to decline with current interest rate environment; pro forma tax rate targeted at 22%-23% in 2024.

- No specific details on the current or expected order book or pending orders are explicitly mentioned on page 5 of the document. - Commentary on capital placements indicates a solid pace with continued interest in da Vinci 5 systems in the U.S. - Europe faces pressure due to government budget constraints impacting capital spending. - China experiences broad stress in healthcare markets with some competition affecting placements. - Overall, placements are expected to shift progressively toward trade-ins as new systems like da Vinci 5 move into broad launch (mid-2025 onwards). - Leasing and usage-based agreements are growing and popular with customers, which may influence order dynamics. - The company expects progressive replacement cycles over multiple years rather than a sudden spike in orders. - Capital deployments remain relatively stable, though with regional variability due to external pressures. No exact order book figures or pending order volumes were disclosed in the provided transcript.